Employers are projecting the healthcare price development to extend by a median of 9% for 2026, and seven.6% after they make plan design modifications, in line with a Tuesday survey from the Enterprise Group on Well being, an employer advocacy group.
“That is the best single-year forecast in additional than a decade,” stated Ellen Kelsay, president and CEO of the Enterprise Group on Well being, throughout a press briefing. “The compounding impact of excessive healthcare development will increase implies that by 2026, healthcare prices (are) projected to be 62% greater than they had been in 2017.”
For the second yr in a row, precise healthcare prices exceeded the forecasted price for employers. In 2024, employers anticipated a 7.1% enhance in healthcare prices, and truly skilled a 7.5% enhance. In 2023, employers anticipated a 6.6% enhance in prices, and skilled a 6.8% enhance. As well as, two-thirds of employers say that rising prices are affecting their skill to supply world advantages.
The Annual Employer Well being Care Technique Survey acquired responses from 121 employers throughout a wide range of industries. These employers collectively cowl 11.6 million folks globally.
Further findings from the survey embody:
1. Prescription drug prices are a serious contributor to healthcare prices. In 2024, pharmacy accounted for a median of 24% of total healthcare spend, in comparison with 21% in 2021. And GLP-1s are partly accountable, with 72% of respondents saying that they drive prices to a “very nice extent” or a “nice extent.” One other 61% stated the identical about high-cost therapies.
2. Virtually all employers cowl GLP-1s for diabetes, whereas 73% cowl them for weight problems. And about 79% of employers stated they’re seeing elevated utilization of weight problems remedies. In terms of masking GLP-1s for weight problems, the commonest utilization administration techniques are prior authorization, requiring participation in a weight administration program and assembly a sure physique mass index threshold.
3. When requested what circumstances are driving prices, 88% stated most cancers, 71% stated musculoskeletal circumstances and 35% cited cardiovascular circumstances. That is the fourth yr in a row by which most cancers is the highest situation contributing to price. To deal with most cancers prices, many employers are increasing protection of most cancers screenings, together with for colon most cancers, breast most cancers and pores and skin most cancers. About half of the respondents additionally stated that they may provide entry to facilities of excellence for most cancers in 2026.
4. To scale back healthcare prices, employers’ high methods embody leveraging the request for proposal course of to get higher pricing from incumbents or new distributors, eliminating lower-utilized applications, changing underperforming distributors, and limiting protection for GLP-1s.
5. About 17% of employers have adopted a non-traditional or different well being plan, whereas 7% are including it in 2026 and 36% are contemplating it for 2027 or 2028. As well as, 16% are utilizing a clear pharmacy profit supervisor, whereas 11% are including one in 2026 and 43% are contemplating it in 2027 or 2028. Nonetheless, switching to a brand new pharmacy pricing or contracting mannequin doesn’t come with out its challenges, together with “issue of calculating the monetary influence of the conversion and no urge for food for member disruption,” the report acknowledged.
6. Employers are additionally taking note of a number of coverage initiatives. About 85% of respondents need the federal government to guard the tax remedy of employer well being protection, 81% need the federal government to guard ERISA preemption and 62% need the federal government to handle prescription drug pricing. As well as, 66% of employers stated they’re involved or very involved that modifications to authorities applications (comparable to Medicare and Medicaid) will hurt employer-sponsored protection.
This wasn’t stunning because it aligns with “long-held employer beliefs that efforts to cut back prices for applications like Medicare and Medicaid will usually end in price shifting to employer-sponsored plans,” stated Brenna Shebel, vice chairman of the Enterprise Group on Well being, through the press briefing.
Picture: PM Photographs, Getty Photographs
